{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-195397","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.572710+00:00","generated_at":"2026-05-31T11:51:12.857753+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA approves Voranigo; Royalty Pharma pays $905M milestone, expects >$150M/yr royalties","bullets":["FDA approved Voranigo (vorasidenib) for IDH1/2 mutant diffuse glioma on August 6, 2024.","Royalty Pharma pays $905M to Agios upon approval under May 2024 royalty agreement.","Royalty Pharma receives 15% royalty on U.S. net sales up to $1B, 12% above $1B.","Peak annual sales projected >$1B; annual royalties >$150M through 2038."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-195397","json":"https://secwatch.observer/filing/0001193125-24-195397.json","markdown":"https://secwatch.observer/filing/0001193125-24-195397.md","text":"https://secwatch.observer/filing/0001193125-24-195397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524195397/0001193125-24-195397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524195397/d868175d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:51:12.857753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}